Ribavirin aerosol in hospitalized adults with respiratory distress and <scp>COVID</scp> ‐19: An open‐label trial-Reference-Cited by-同舟云学术

Ribavirin aerosol in hospitalized adults with respiratory distress and COVID ‐19: An open‐label trial

Published:2022-11-03 Issue:1 Volume:16 Page:165-174
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Poulakou Garyfallia¹,Barakat Maxime²^ORCID,Israel Robert J.³,Bacci Marcelo R.⁴,Abril Juan Francisco Moreno Hoyos,Álvarez Samuel Navarro,Fonseca Fernando Luiz Affonso,Kainis Ilias,Kalomoiri Smaragdi,Leontis Konstantinos,Metallidis Symeon,Panagopoulos Periklis,Papastamopoulos Vasileios,Ragognete Henrique Gitti,Ramacciotti Eduardo,Rapti Vasiliki,Sakka Vissaria,Syrigos Konstantinos N.,Tsoukalas George,Xynogalas Ioannis,

Affiliation:

1. Third Department of Internal Medicine, “Sotiria” General Hospital of Chest Diseases National and Kapodistrian University of Athens School of Medicine Athens Greece

2. Bausch Health Laval Quebec Canada

3. Bausch Health Bridgewater New Jersey USA

4. Clinical Analysis Division, Praxis Pesquisa Medica Centro Universitário Faculdade de Medicina do ABC Santo Andre São Paulo Brazil

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13436

Reference43 articles.

1. COVID-19, SARS and MERS: are they closely related?

2. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update

3. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management

4. Reducing mortality from 2019-nCoV: host-directed therapies should be an option

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nebulized inhalation of plasma-activated water in the treatment of progressive moderate COVID-19 patients with antiviral treatment failure: a randomized controlled pilot trial;BMC Infectious Diseases;2024-09-12

2. Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation;Pharmaceutics;2024-08-26

3. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery;Expert Opinion on Drug Discovery;2024-07-30

4. Clinico-Virological Outcomes and Mutational Profile of SARS-CoV-2 in Adults Treated with Ribavirin Aerosol for COVID-19 Pneumonia;Microorganisms;2024-06-05